PISCTWAY, N.J. – Camber Pharmaceuticals is proud to announce the launch of eltrombopag, the AB Rated generic for Promacta.
Through Camber’s copayment program, eligible patients may pay as little as $0 out-of-pocket. Visit Camber’s eltrombopag web page for full offer details.
“For years, many patients have struggled to afford this life-saving therapy,” said Kon Ostaficiuk, president of Camber Pharmaceuticals. “We are excited to offer this important medication with a copay assistance program.”
Eltrombopag is indicated for thrombocytopenia—a serious condition affecting platelet counts—and for aplastic anemia, a condition that impacts the production of new blood cells.
A summary of eltrombopag’s indications (oral suspension and tablets) appears below:
• Persistent or chronic Immune Thrombocytopenia (ITP) in all patients 1 year and older insufficiently responsive to other treatments and only in patients with increased risk of bleeding
• Thrombocytopenia only in chronic hepatitis C patients whose clinical condition prevents or limits initiation/maintenance of interferon-based therapy
• Patients with severe aplastic anemia who are insufficiently responsive to immunosuppressive therapy.
Dosage Availability:
• Camber’s eltrombopag for oral suspension is available in cartons of 30 unit-dose packets in 12.5 mg and 25 mg strengths.
• Camber’s eltrombopag tablets are available in 30-count bottles in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.
To learn more about Camber’s eltrombopag—the AB Rated generic for Promacta—please visit www.CamberEltrombopag.com or contact your Camber representative.
